Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced that it has signed a statement of intent with the World Health Organization (WHO) to supply free of charge of a primary medicine for the treatment of lymphatic filariasis. The statement was signed by Mr. Haruo Naito, Eisai President and CEO, and Dr. Margaret Chan, Director-General of WHO. This is the first time a Japanese pharmaceutical company has established a partnership with WHO in an effort to combat the global health issue of neglected tropical diseases...
More...
More...